Premature infants are at high risk for developing bronchopulmonary dysplasia (BPD), characterized by chronic inflammation and inhibition of lung development, which we have recently identified as being modulated by microRNAs (miRNAs) and alterations in the airway microbiome. Exosomes and exosomal miRNAs may regulate cell differentiation and tissue and organ development. We discovered that tracheal aspirates from infants with severe BPD had increased numbers of, but smaller, exosomes compared with term controls. Similarly, bronchoalveolar lavage fluid from hyperoxia-exposed mice (an animal model of BPD) and supernatants from hyperoxia-exposed human bronchial epithelial cells (in vitro model of BPD) had increased exosomes compared with air controls. Next, in a prospective cohort study of tracheal aspirates obtained at birth from extremely preterm infants, utilizing independent discovery and validation cohorts, we identified unbiased exosomal miRNA signatures predictive of severe BPD. The strongest signal of reduced miR-876-3p in BPD-susceptible compared with BPD-resistant infants was confirmed in the animal model and in vitro models of BPD. In addition, based on our recent discovery of increased Proteobacteria in the airway microbiome being associated with BPD, we developed potentially novel in vivo and in vitro models for BPD combining Proteobacterial LPS and hyperoxia exposure. Addition of LPS led to a larger reduction in exosomal miR 876-3p in both hyperoxia and normoxia compared with hyperoxia alone, thus indicating a potential mechanism by which alterations in microbiota can suppress miR 876-3p. Gain of function of miR 876-3p improved the alveolar architecture in the in vivo BPD model, demonstrating a causal link between miR 876-3p and BPD. In summary, we provide evidence for the strong predictive biomarker potential of miR 876-3p in severe BPD. We also provide insights on the pathogenesis of neonatal lung disease, as modulated by hyperoxia and microbial product–induced changes in exosomal miRNA 876-3p, which could be targeted for future therapeutic development.
Pulmonary drug delivery presents a unique opportunity to target lower airway inflammation, which is often characterized by the massive recruitment of neutrophils from blood. However, specific therapies are lacking modulation of airway neutrophil function, and difficult challenges must be overcome to achieve therapeutic efficacy against pulmonary inflammation, notably drug hydrophobicity, mucociliary and macrophage-dependent clearance, and high extracellular protease burden. Here, we present a multistage, aerodynamically favorable delivery platform that uses extracellular proteolysis to its advantage to deliver nanoparticle-embedded hydrophobic drugs to neutrophils within the lower airways. Our design consists of a self-regulated nanoparticle-in-microgel system, in which microgel activation is triggered by extracellular elastase (degranulated by inflammatory neutrophils), and nanoparticles are loaded with Nexinhib20, a potent neutrophil degranulation inhibitor. Successful in vivo delivery of Nexinhib20 to the airways and into neutrophils promoted resolution of the inflammatory response by dampening neutrophil recruitment and degranulation, proinflammatory cytokine production in both airway and systemic compartments, as well as the presence of neutrophil-derived pathological extracellular vesicles in the lung fluid. Our findings showcase a new platform that overcomes challenges in pulmonary drug delivery and allows customization to match the proteolytic footprint of given diseases.
Introduction: Patients with chronic obstructive pulmonary disease (COPD) often develop cardiovascular disorders such as right ventricular hypertrophy (RVH) and pulmonary hypertension (PH). We hypothesized that the neutrophil chemoattractant proline-glycine-proline (PGP), generated by the stepwise proteolytic cleavage of collagen by matrix metalloproteinases and prolyl endopeptidase (PE), would be involved in ongoing PH pathogenesis. Methods: Mice were administered with acetylated PGP (Ac-PGP) (250 µg/dose) intratracheally for 6 and 10 weeks or exposed to cigarette smoke for 6 weeks to evaluate lung inflammation and RVH. To further elucidate the impact of PGP on pulmonary vascular remodeling, the PE inhibitor benzyloxycarbony-proline-prolinal (ZPP) was intratracheally administered in a 6-week smoking model. Results: In mice treated with Ac-PGP at 6 weeks and 10 weeks, there was increased right ventricular systolic pressures (RVSP) when compared to the control group. The average ratio of RV/(LV+S) also showed significant increase with Ac-PGP administration. Ac-PGP levels in the blood was significantly increased after 6 weeks of smoke exposure. Treating the mice with ZPP intratracheally prior to smoke exposure significantly decreased inflammation in the lungs and prevented mice from developing PH. Furthermore, nitrite and nitrate levels in blood were elevated after smoke exposure and the nitrite/nitrate ratio returned to baseline levels after ZPP treatment, suggesting reduced oxidative stress. Conclusion: These results demonstrate that Ac-PGP induced the development of PH and that targeting of PGP peptides in a smoke model affects the development of RVH and PH.